Value
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.6 |
| P/S | 10.0 |
| EV/EBITDA | 7.4 |
| Fwd P/E | 9.5 |
| PEG | 8.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 8.6x
- ▸PEG: 0.83
- ▸Attractively valued
CI · Why this verdict
Why The Cigna (CI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The business quality profile — spanning return on assets, operating margin, and competitive positioning — sits marginally below the minimum acceptable level, with no recognized competitive moat identified, a gap that limits the premium the business can command through a downturn and makes the investment case dependent on continued earnings delivery rather than structural advantage. Warnings | Piotroski F-Score rises to 9 out of 9 and operating margin shows measurable improvement above current levels for 2 consecutive quarters. | →Stable |
| CounterA Piotroski F-Score of 7 out of 9 confirms adequate balance-sheet health, and the FCF conversion rate above zero indicates the business is generating real cash; quality concerns at the margin may overstate the structural weakness relative to the durable cash generation the business maintains. | ||
The company has beaten analyst consensus estimates in each of the last four quarters, suggesting a reliable, though modest, pattern of delivery — average positive surprise of approximately 2% — that supports the credibility of forward earnings estimates and reduces the likelihood of a near-term negative shock. Catalyst breakdown | The beat streak extends to 6 consecutive quarters, with average positive earnings surprise remaining above 1% over the next two reporting periods. | →Stable |
| CounterAn average surprise of only about 2% is narrow enough to flip negative on a single quarter of cost pressure; without meaningful guidance conservatism, any revenue shortfall or medical-cost increase could produce a miss that breaks the streak entirely and resets investor expectations. | ||
A forward P/E of 8.8x and a PEG ratio of 0.88 place the stock among the more attractively priced names in its peer group, with peer comparison data confirming the company ranks favorably on earnings-based multiples and return on equity relative to competitors. Valuation breakdown | Forward P/E remains below 12x as earnings grow, validating the value thesis without requiring multiple expansion. | →Stable |
| CounterLow multiples in healthcare services plans often reflect structurally compressed margins and regulatory exposure rather than genuine cheapness; a gross margin component near zero and operating margins well below what a differentiated franchise would generate suggest the discount may be warranted rather than an opportunity. | ||
With only 4.4% of headroom to the analyst consensus target against 8.5% of potential downside, the current entry point offers a risk/reward ratio of roughly 0.5-to-1 — well below the approximately 1.5-to-1 level the setup requires to be actionable — and an elevated put/call ratio of 8.13 in the options market adds a further cautionary signal. Price targets | Upside to the analyst consensus target expands to more than 15% from current levels, restoring a risk/reward ratio of at least 1.5-to-1 before the setup becomes attractive. | →Stable |
| CounterThe underlying technical setup is constructive — golden cross, above all moving averages, rising volume accumulation — and four quarters of earnings delivery have been consistent; continued execution could cause the price target gap to close from the bottom rather than from above. | ||
The business quality profile — spanning return on assets, operating margin, and competitive positioning — sits marginally below the minimum acceptable level, with no recognized competitive moat identified, a gap that limits the premium the business can command through a downturn and makes the investment case dependent on continued earnings delivery rather than structural advantage.
→StableWarnings
- Expectation
- Piotroski F-Score rises to 9 out of 9 and operating margin shows measurable improvement above current levels for 2 consecutive quarters.
CounterA Piotroski F-Score of 7 out of 9 confirms adequate balance-sheet health, and the FCF conversion rate above zero indicates the business is generating real cash; quality concerns at the margin may overstate the structural weakness relative to the durable cash generation the business maintains.
The company has beaten analyst consensus estimates in each of the last four quarters, suggesting a reliable, though modest, pattern of delivery — average positive surprise of approximately 2% — that supports the credibility of forward earnings estimates and reduces the likelihood of a near-term negative shock.
→StableCatalyst breakdown
- Expectation
- The beat streak extends to 6 consecutive quarters, with average positive earnings surprise remaining above 1% over the next two reporting periods.
CounterAn average surprise of only about 2% is narrow enough to flip negative on a single quarter of cost pressure; without meaningful guidance conservatism, any revenue shortfall or medical-cost increase could produce a miss that breaks the streak entirely and resets investor expectations.
A forward P/E of 8.8x and a PEG ratio of 0.88 place the stock among the more attractively priced names in its peer group, with peer comparison data confirming the company ranks favorably on earnings-based multiples and return on equity relative to competitors.
→StableValuation breakdown
- Expectation
- Forward P/E remains below 12x as earnings grow, validating the value thesis without requiring multiple expansion.
CounterLow multiples in healthcare services plans often reflect structurally compressed margins and regulatory exposure rather than genuine cheapness; a gross margin component near zero and operating margins well below what a differentiated franchise would generate suggest the discount may be warranted rather than an opportunity.
With only 4.4% of headroom to the analyst consensus target against 8.5% of potential downside, the current entry point offers a risk/reward ratio of roughly 0.5-to-1 — well below the approximately 1.5-to-1 level the setup requires to be actionable — and an elevated put/call ratio of 8.13 in the options market adds a further cautionary signal.
→StablePrice targets
- Expectation
- Upside to the analyst consensus target expands to more than 15% from current levels, restoring a risk/reward ratio of at least 1.5-to-1 before the setup becomes attractive.
CounterThe underlying technical setup is constructive — golden cross, above all moving averages, rising volume accumulation — and four quarters of earnings delivery have been consistent; continued execution could cause the price target gap to close from the bottom rather than from above.
TrendMatrix Research · core thesis
Engine thesis — one sentence
The company delivers consistent earnings beats — four consecutive quarters each with a modest positive surprise — and trades at an undemanding forward P/E of 8.8x, but quality marginally below the minimum acceptable level, the absence of a recognized competitive moat, and a risk/reward geometry of only 4.4% upside against 8.5% downside leave the current setup unattractive for new capital despite constructive price action.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.4 |
| ROA | 3.2 |
| Gross margin | 0.0 |
| Op margin | 2.2 |
| Net margin | 1.1 |
| Current ratio | 3.3 |
| FCF quality | 7.5 |
| Moat | 5.0 |
| Piotroski F | 7.8 |
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
5.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.7 |
| EPS growth | 7.8 |
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 4.9 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 7.5 |
| Price target | 7.5 |
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $59,382,638 (0.078% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.5 |
| quality rank | 7.7 |
| growth rank | 3.6 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 4.5 |
| 52w position | 7.4 |
| gap | 5.0 |
Risk (lower is worse)
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.5 |
| days to cover | 5.9 |
| volatility | 6.7 |
| put call | 5.5 |
| implied vol | 6.2 |
| beta | 10.0 |
| debt equity | 6.6 |
- ▸Concentration risks: 5 MED (10-K Item 1A)
Catalyst
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 3.5 |
| dividend safety | 7.0 |
| news activity | 7.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 217.0%
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (0)
none
Reward-to-Risk
1.30
Upside
+6.5%
Downside
5.0%
Sizing output
AVOID
SetupRange Bound — RSI 43 mid-range, Bollinger mid-band
EdgeCatalyst-Driven — Earnings in 27d with 4/4 beat streak
SuitabilityModerate — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.2 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.3<1.5@spot.
The strongest dimensions are Value at 8.2, Risk (lower is worse) at 7.1, and Sentiment at 6.7; the weakest are Insider at 3.8, Quality at 3.9, and Technical at 5.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Execution
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Attractive Valuation Vs Peers
Trip ifForward P/E expands above 14x from the current 8.8x as the stock re-rates on improved sentiment.
- P3Unfavorable Risk Reward Geometry
Trip ifUpside to analyst consensus target exceeds 15% from the current price of $293.83.
- P4Quality Below Minimum Threshold
Trip ifPiotroski F-Score rises to 9 out of 9 for 2 consecutive quarters.